Hong Kong stocks concept tracking | Lite version of Simvastatin peptide launched in China market Domestic weight loss drugs receive attention (with concept stocks)

Danish pharmaceutical giant Novo Nordisk A/S Sponsored ADR Class B (NVO.US) has launched its hugely popular "miracle weight loss drug" Wegovy (semaglutide) in the Chinese market. The price is much cheaper compared to the sales price in the United States, which also means that Novo Nordisk A/S Sponsored ADR Class B is making a major entrance into a large and rapidly growing market. It is understood that the "blood sugar-lowering version" of semaglutide (marketed as Ozempic) has already been approved in China, but only for the treatment of diabetes. With the arrival of Wegovy, the "weight loss version" of semaglutide is officially entering the potentially huge Chinese market. On the news side, the world's first glucagon-like peptide-1 receptor agonist (GLP-1) weekly formulation for long-term weight management, Norjing Yingshun, has issued the first batch of prescriptions at the Shanghai Fudan University Affiliated Zhongshan Hospital. On June 25th, the National Medical Products Administration (NMPA) approved the market application for Norjing Yingshun in China. On November 17th, Novo Nordisk A/S Sponsored ADR Class B announced that the weight loss version of semaglutide was officially launched for commercialization in China. Novo Nordisk A/S Sponsored ADR Class B's main competitor, the U.S.-based pharmaceutical giant Eli Lilly, has also received official approval for its weight loss drug in China, while some domestic biotechnology companies in China are also actively developing competitive weight loss drugs. The weight loss drug market still has vast prospects, with most institutions predicting that the market size will reach billions of dollars by the end of this decade. In addition to Eli Lilly and Novo Nordisk A/S Sponsored ADR Class B, which almost monopolize the weight loss drug market, many pharmaceutical companies are intensifying their research and development of weight loss drugs to vie for a share of this highly potential market. Domestic weight loss drug-related companies: INNOVENT BIO (01801): INNOVENT BIO's GLP-1/GCG dual agonist mazdutide is at the forefront of domestic GLP-1 innovative drugs. Previously, the drug's two NDAs (New Drug Applications) were accepted domestically, with indications including long-term weight management for the obese or overweight population and treatment of type 2 diabetes. The weight loss indication is expected to be approved in the first half of next year. BOCI Research believes that INNOVENT BIO's clinical-stage weight loss drug Mazdutide is likely to replicate Eli Lilly's success in Western countries with its blockbuster weight loss drug. The institution expects that INNOVENT BIO's GLP1R/GCGR dual-target global innovative product Mazdutide has entered the application for listing stage and is expected to be approved for listing in the next two years.